Insulin analogues with improved absorption characteristics.
The insulin preparations available today are not ideal for therapy as s.c. injection does not provide a physiological insulin profile. With the aim to improve the absorption properties recombinant DNA technology has been utilized to design novel insulin molecules with changed physico-chemical characteristics and hence altered subcutaneous absorption kinetics. Soluble, long-acting human insulin analogues in which the isoelectric point has been increased from 5.4 to approx. 7 are absorbed very slowly, providing a more constant basal insulin delivery with lower day-to-day variation than present protracted preparations. In addition they have better storage stability. Rapid-acting human insulin analogues with largely reduced self-association are absorbed substantially faster from subcutaneous tissue than current regular insulin and thus are better suited for bolus injection. The absorption kinetics of these analogues have been able to explain the mechanism behind the dose effect on insulin absorption rate.
Brange
J
J
Novo Research Institute, Bagsvaerd, Denmark.
Hansen
J F
JF
Langkjaer
L
L
Markussen
J
J
Ribel
U
U
Sørensen
A R
AR
D000042:Absorption; D003692:Delayed-Action Preparations; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D007328:Insulin